Comparison of ß-lactam plus aminoglycoside versus ß-lactam plus fluoroquinolone empirical therapy in serious nosocomial infections due to Gram-negative bacilliFootnote

Results were previously presented at the 53rd ICAAC in Denver, CO 2013 (Poster number K-173).

References

• Rahal JJ. Antimicrobial resistance among and therapeutic options against gram-negative pathogens. Clin Inf Dis. 2009 Aug;49(s1):S4–S10.10.1086/599995
   Google Scholar
• Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013 Feb;41(2):580–637.10.1097/CCM.0b013e31827e83af
   PubMed Web of Science ®Google Scholar
• American Thoracic S. Infectious diseases society of A. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 Feb;171(4):388–416.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011 Feb;52(4):e56–93.10.1093/cid/cir073
   PubMed Web of Science ®Google Scholar
• Boyd N, Nailor MD. Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the society of infectious diseases pharmacists. Pharmacotherapy. 2011 Nov;31(11):1073–84.10.1592/phco.31.11.1073
   PubMed Web of Science ®Google Scholar
• Johnson SJ, Ernst EJ, Moores KG. Is double coverage of gram-negative organisms necessary? Am J Health Syst Pharm. 2011 Jan;68(2):119–24.10.2146/ajhp090360
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003 Dec;31(12):2742–51.10.1097/01.CCM.0000098031.24329.10
   PubMed Web of Science ®Google Scholar
• Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009 Nov;136(5):1237–48.10.1378/chest.09-0087
   PubMed Web of Science ®Google Scholar
• Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010 May;54(5):1742–8.10.1128/AAC.01365-09
   PubMed Web of Science ®Google Scholar
• Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH. Inappropriate antibiotic therapy in gram-negative sepsis increases hospital length of stay. Crit Care Med. 2011 Jan;39(1):46–51.10.1097/CCM.0b013e3181fa41a7
   PubMed Web of Science ®Google Scholar
• Martinez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, Marco F, et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother. 2010 Sep;54(9):3590–6.10.1128/AAC.00115-10
   PubMed Web of Science ®Google Scholar
• Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. The Cochrane database of systematic reviews. 2014;1:CD003344.
   Google Scholar
• Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Critical Care Med. 2010 Sep;38(9):1773–85.10.1097/CCM.0b013e3181eb3ccd
   PubMed Web of Science ®Google Scholar
• Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2003 Sep;47(9):2756–64.10.1128/AAC.47.9.2756-2764.2003
   PubMed Web of Science ®Google Scholar
• Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med. 2010 Aug;38(8):1651–64.10.1097/CCM.0b013e3181e96b91
   PubMed Web of Science ®Google Scholar
• Al-Hasan MN, Wilson JW, Lahr BD, Thomsen KM, Eckel-Passow JE, Vetter EA, et al. Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli. Antimicrob Agents Chemother. 2009 Apr;53(4):1386–94.10.1128/AAC.01231-08
   PubMed Web of Science ®Google Scholar
• Rhomberg PR, Jones RN. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis. 2009 Dec;65(4):414–26.10.1016/j.diagmicrobio.2009.08.020
   PubMed Web of Science ®Google Scholar
• Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward gram-negative isolates from the meropenem yearly susceptibility test information collection program (USA). Diagn Microbiol Infect Dis. 2006 Sep;56(1):57–62.10.1016/j.diagmicrobio.2005.12.009
   PubMed Web of Science ®Google Scholar
• Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among gram-negative bacilli isolated from Latin America: results from SENTRY antimicrobial surveillance program (Latin America, 2008-2010). Diagn Microbiol Infect Dis. 2012 Aug;73(4):354–60.10.1016/j.diagmicrobio.2012.04.007
   PubMed Web of Science ®Google Scholar
• Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003 Apr;29(4):530–8.10.1007/s00134-003-1662-x
   PubMedGoogle Scholar
• Samonis G, Koutsounaki E, Karageorgopoulos DE, Mitsikostas P, Kalpadaki C, Bozionelou V, et al. Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. Eur J Clin Microbiol Inf Dis. 2012 Jul;31(7):1389–98.
   PubMed Web of Science ®Google Scholar
• Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest. 2006 Sep;130(3):787–93.10.1378/chest.130.3.787
   PubMed Web of Science ®Google Scholar
• Ahn JY, Song JE, Kim MH, Choi H, Kim JK, Ann HW, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case-control study. Am J Inf Control. 2014 Jun;42(6):621–5.10.1016/j.ajic.2014.02.024
   PubMed Web of Science ®Google Scholar
• Kim T, Chong YP, Park SY, Jeon MH, Choo EJ, Chung JW, et al. Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter study in Korea. Diagn Microbiol Infect Dis. 2014 Apr;78(4):457–61.10.1016/j.diagmicrobio.2013.08.011
   PubMed Web of Science ®Google Scholar
• Davies SW, Efird JT, Guidry CA, Hranjec T, Metzger R, Swenson BR, et al. Does it matter if we get it right? Impact of appropriateness of empiric antimicrobial therapy among surgical patients. Shock. 2014 Sep;42(3):185–91.10.1097/SHK.0000000000000192
   PubMed Web of Science ®Google Scholar
• Frakking FN, Rottier WC, Dorigo-Zetsma JW, van Hattem JM, van Hees BC, Kluytmans JA, et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-beta-lactamase-producing bacteria. Antimicrob Agents Chemother. 2013 Jul;57(7):3092–9.10.1128/AAC.01523-12
   PubMed Web of Science ®Google Scholar
• Osthoff M, McGuinness SL, Wagen AZ, Eisen DP. Urinary tract infections due to extended-spectrum beta-lactamase-producing gram-negative bacteria: identification of risk factors and outcome predictors in an Australian tertiary referral hospital. Int J Inf Dis. 2015 May;34:79–83.10.1016/j.ijid.2015.03.006
   PubMed Web of Science ®Google Scholar
• Özgür ES, Horasan ES, Karaca K, Ersöz G, Nayci Atis S, Kaya A. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. Am J Inf Control. 2014 Feb;42(2):206–8.10.1016/j.ajic.2013.09.003
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Weycker D, Barron R, Li X, Wu H, Oster G, et al. Prevalence of antibiotic resistance in US hospitals. Diagn Microbiol Infect Dis. 2014 Mar;78(3):255–62.10.1016/j.diagmicrobio.2013.11.011
   PubMed Web of Science ®Google Scholar
• Tuon FF, Rocha JL, Toledo P, Arend LN, Dias CH, Leite TM, et al. Risk factors for KPC-producing Klebsiella pneumoniae bacteremia. Braz J Infect Dis. 2012 Sep–Oct;16(5):416–9.10.1016/j.bjid.2012.08.006
   PubMed Web of Science ®Google Scholar
• Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008 Jan;46(s1):S19–31.10.1086/528816
   PubMedGoogle Scholar
• Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest. 2005 Aug;128(2):545–52.10.1378/chest.128.2.545
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine. 2006 Jun;34(6):1589–96.10.1097/01.CCM.0000217961.75225.E9
   PubMed Web of Science ®Google Scholar